PleniDose™ Gantry — one platform, two cartridge architectures

The glass may vary. The dose must not.

The same motion platform and datum-control architecture serve both the dual-chamber Lyoprester and liquid Liquiprester lines. The interchangeable rod-holder assembly establishes the cartridge format, while the software recipe and the product-specific filling sequence determine how each cartridge is processed. One shared machine and one shared control philosophy — not one identical process.

PleniDose™ Gantry

01 //  One gantry, two products

Most filling lines are built for one format. A cartridge line that fills a dual-chamber cartridge — a freeze-dried cake in one compartment, its matched diluent in the other — looks nothing like a line that fills a single liquid cartridge. Panacea took the opposite path: build one gantry and let the tooling do the switching.

The motion platform, the coordinate system and the datum-control philosophy remain shared. The active fluid operations, the process recipe and the finishing sequence are selected for the cartridge line being produced. What changes between product lines is the rod-holder assembly — the tooling that presents and registers the cartridge bodies to the machine; the gantry then runs the product-specific Lyoprester® or Liquiprester™ process recipe. Fit the dual-chamber rod-holder assembly and the gantry produces a Lyoprester® cartridge →; fit the liquid rod-holder assembly and the very same gantry produces a Liquiprester™ cartridge →. Either cartridge architecture may also support a compatible Peptourbillon™ programme where the formulation and process have been specifically developed for it — a freeze-dried cake in the dual-chamber body, or a curated blend held in a formulation-specific liquid architecture.

Keep one platform for both cartridges, and the dose discipline stops being a per-product argument — it becomes a property of the machine.

02 //  What the gantry controls

The platform's job is to turn a formulation and an empty cartridge into a finished, controlled-dose unit while controlling the variables capable of causing dose drift. The gantry provides six shared controlled functions common to both lines, then runs the product-specific stages for whichever cartridge is in tooling.

Both lines share the six controlled functions above; the completion medium, the Cryoviscous™ conditioning and the dual-cannula drawback are Liquiprester-specific, while dual-chamber staging and Vana Machine™ preparation are Lyoprester-specific. One shared machine and control philosophy — not one identical process.

03 //  Slow top-up, fast drawback

The completion move is the signature of the platform, and its rhythm matters. The principal-additive-free ElimiVoid™ completion medium is added slowly and gently, delivered above a transient first-contact interfacial barrier so the incoming liquid is designed not to stir the API-containing layer beneath it. Then the finishing cannula withdraws rapidly at the calibrated meniscus, removing the excess API-free completion medium in a single quick motion — without moving the rear plunger, so the API-containing primary aliquot stays protected below the withdrawal zone.

The asymmetry is the point. A slow, above-barrier addition keeps the layers ordered; a fast, precise drawback removes the excess completion medium before the layers have a chance to intermix. That interface, per Panacea's corrected doctrine, is a single-cycle, first-contact phenomenon: when the completion medium first contacts the Cryoviscous™ primary formulation, a transient barrier forms under the defined process conditions and protects the primary aliquot during completion and excess withdrawal. After controlled warming, the layers homogenise above the formulation-specific interface-release temperature, and the process does not re-form the original interface during subsequent qualified cooling cycles. It is a contact-induced structuring, not a repeatable temperature-driven two-phase system.

Gentle in, quick out — the addition is unhurried, the finishing withdrawal is fast, and the plunger never moves.

04 //  No visible air bubble, argon-conditioned

The finished Liquiprester™ carries no visible air bubble, within a near-airless, oxygen-depleted and argon-conditioned internal environment — the product of three cooperating steps in the process stack, each with its own site, each with a distinct role:

• OxyDeplete™ reduces the dissolved and entrained atmospheric gases in the fill liquids before the cartridge is completed.
• ArgonLock™ applies controlled argon conditioning that reduces oxygen exposure and supports oxygen removal by mass transfer, establishing an argon-enriched liquid and closure environment.
• ElimiVoid™ replaces the deliberate compressible front void with completion medium, so the finished cartridge shows no visible air bubble.

Together they remove the intended air gap and drive residual oxygen low. The claim is precise and honest: not that every molecule of dissolved gas is gone, but that the deliberate compressible front void is eliminated and oxygen exposure is reduced. Around all of this sits RedoxVault™, Panacea's formulation-specific oxidative-protection architecture, whose implementation is selected according to the active ingredients, excipients and phase structure of each formulation — not one identical mechanism in every cartridge.

05 //  Process-control philosophy

The gantry is built on a simple engineering stance: a dose is a controlled quantity, not a hopeful one. Every step above is defined by a measured reference — a datum, a metered volume, a conditioned viscosity, a calibrated meniscus — so that the finished cartridge is a consequence of the machine's control, not of the operator's hand. That is why one platform can serve two very different cartridges without the dose discipline changing: the discipline lives in the motion control and the datums, and the tooling merely presents the glass.

Watching over the wider peptide cycle is the S3Pulse™ biointegrity engine, which keeps the record so each cartridge is the preparation the formulator intended — the same discipline Panacea brings to every fragile chain, here in the service of a controlled fill that leaves no visible air bubble.

06 //  The idea, in one table

Named steps describe the platform's public architecture. PleniDose™ is a proprietary Panacea Bio Chem platform designed and invented by Bogdan Dicoias; its underlying machine parameters and process specifications are not published. No dose, outcome or health claim is made here.

07 //  The engineering lineage

07b //  The machine, running

One gantry runs both product lines, controlled by S3Pulse and KineticON™: Lyoprester builds the dual-chamber cartridge, Liquiprester fills and closes the liquid one.

Lyoprester — dual chamber

1. Peptidic liquid aliquoting, prior to lyophilization
2. Middle plunger insertion
3. P-EARLs aliquoting
4. Top plunger enclosing of P-EARLs, without air bubbles
5. Cartridge enclosure by crimping the alu/septa cap

Liquiprester — liquid cartridge

1. Plunger insertion
2. Peptidic liquid
3. Cartridge closure, without air bubbles

Why the closure is the product

Watch the Liquiprester sequence and there is no air bubble left behind the plunger. That is not cosmetic. Trapped oxygen does not sit quietly in a cartridge — it reacts, and it spends the shelf life of the peptide doing so. Panacea removes it before closure with OxyDeplete™, dissolves argon into the peptidic liquid and seals under it with ArgonLock™, and places the trace metal catalysts that would otherwise drive oxidation out of reach with RedoxVault™. Together with the rest of the Panacea stack, that is what makes this peptidic liquid cartridge the longest-lived on the market.

What the gantry makes possible downstream

Precision at this stage is what later technologies stand on. IncreSure™ can verify the API in each pen increment because the piston travel behind that increment was a measured motion, not a printed dial figure. ElimiVoid™ can clear the compressible void ahead of the dose without moving the rear plunger or withdrawing a microlitre of API, because the machine knows exactly which axis may move and which must not. And Cryoviscous™ holds the formulation cold, stiff and slow so it can be placed exactly — which changes the force, the timing and the settle the gantry has to get right. Each one is a promise about a movement, kept by S3Pulse and KineticON™.

08 //  Where the platform reaches furthest

A shared, controlled-dose filling platform is a broad, high-leverage idea. Directions where it matters most include:

• Fragile peptide payloads. Formulations that will not tolerate turbulence or an air pocket benefit most from Cryoviscous™ conditioning and a no-visible-air-bubble finish.
• Multi-format product families. A line that must make both a dual-chamber and a liquid cartridge gains from sharing one datumed platform rather than running two.
• Pen-indexed delivery. A fixed, pen-compatible plunger datum is what lets an EZnject™ pen and IncreSure™ map a cartridge into characterised mechanical increments mapped to recoverable API output.
• Oxidation-sensitive actives. The near-airless, low-oxygen internal environment pairs naturally with formulation-specific oxidative protection such as RedoxVault™, whose implementation is selected per formulation rather than a single universal mechanism.

These fields are offered as a map of engineering and product opportunity and future research direction, not as indications or advice.

Frequently asked

Trending in the field

References & further reading

1. ISO 11608-1 and ISO 11608-3 — needle-based injection systems for medical use: requirements and test methods for the delivery system and for the containers and cartridges, including dose accuracy across the delivery stroke. Named standard; further reading: pen-injector systems (Wikipedia).
2. ISO 13926 series — pen systems: glass cartridge and plunger/stopper dimensions for pen-injectors. Named standard; further reading: autoinjector / cartridge systems (Wikipedia).
3. Sterile drug products produced by aseptic processing — FDA current good manufacturing practice guidance and EU GMP Annex 1 on sterile medicinal products; automated sterile cartridge filling replaces variable manual filling. FDA aseptic-processing guidance; aseptic processing (Wikipedia).
4. Stopper / plunger-position and pen dose-accuracy in cartridge-based injection systems — the datum reference that governs delivered dose. Further reading: injection systems (Wikipedia).
5. Fill-finish headspace and dissolved-oxygen (DO) control in parenteral packaging — reducing oxidative exposure of the finished container. Further reading: oxygen scavenging (Wikipedia).
6. Interfacial gelation and low-temperature rheology of peptide and protein solutions — the physical basis for a temperature-conditioned, high-viscosity completion window. Further reading: rheology (Wikipedia).
7. Automated cartridge filling and motion control — coordinated, repeatable machine movement enabling dose-uniformity across a pen delivery stroke. Further reading: motion control (Wikipedia).
8. Argon as an inert conditioning gas for low-oxygen environments, and freeze-drying (lyophilisation) as the drying route behind the dual-chamber cartridge. Argon (Wikipedia); freeze-drying (Wikipedia).